Product Information
Registration Status: ActiveSIN13407P
GALVUS TABLET 50MG is approved to be sold in Singapore with effective from 2008-02-14. It is marketed by NOVARTIS (SINGAPORE) PTE LTD, with the registration number of SIN13407P.
This product contains Vildagliptin 50mg in the form of TABLET. It is approved for ORAL use.
This product is manufactured by Novartis Pharma Stein AG in SWITZERLAND, andNovartis Farmaceutica SA in SPAIN.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Vildagliptin, previously identified as LAF237, is a new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucaon release by the alpha cells of the islets of Langerhans in the pancreas. It is currently in clinical trials in the U.S. and has been shown to reduce hyperglycemia in type 2 diabetes mellitus. While the drug is still not approved for use in the US, it was approved in Feb 2008 by European Medicines Agency for use within the EU and is listed on the Australian PBS with certain restrictions.
Indication
Used to reduce hyperglycemia in type 2 diabetes mellitus.
Mechanism of Action
Vildagliptin inhibits dipeptidyl peptidase-4 (DPP-4). This in turn inhibits the inactivation of GLP-1 by DPP-4, allowing GLP-1 to potentiate the secretion of insulin in the beta cells. Dipeptidyl peptidase-4's role in blood glucose regulation is thought to be through degradation of GIP and the degradation of GLP-1.
Pharmacokinetics
- Absorption
- Rapidly absorbed following oral administration with an oral bioavailability of greater than 90%.
- Distribution
- Metabolism
- Elimination
Active Ingredient/Synonyms
EQUA | Galvus | Jalra | LAF237 | NVP-LAF-237 | NVP-LAF237 | Vildagliptin | Xiliarx | Vildagliptin |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.